AstraZeneca and Daiichi Sankyo to jointly develop another new cancer treatment

Biopharmaceutical company AstraZeneca has struck a deal with Japanese pharmaceutical company Daiichi Sankyo to jointly develop and market a new medicine to treat lung, breast and other cancers.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen

18 November 2020 Daiichi Sankyo and AstraZeneca have asked the US District Court for the District of Delaware for a declaration that their breast cancer treatment does not infringe a chemotherapy patent owned by biotechnology company Seagen.

Americas

Seagen targets Daiichi in cancer drug suit

22 October 2020 US biotechnology company Seagen has accused Japanese pharmaceutical company Daiichi Sankyo of infringing patents with a recently-approved breast cancer drug.

Big Pharma

AstraZeneca announces new R&D, AI centres in China

11 November 2019 AstraZeneca is planning to build a new global research and development centre in China.